Navigation Links
Evotec Reports Positive Top-Line Results in Phase II Study With EVT 201 in Elderly Insomniacs With Daytime Sleepiness
Date:10/16/2007

2, a MAO-B inhibitor in development for smoking cessation.

On 19 September 2007, Evotec announced that it has entered into a definitive agreement under which Evotec will acquire Renovis, a biopharmaceutical company focused on the discovery and development of drugs for major medical needs in the areas of pain and inflammatory diseases.

http://www.evotec.com

Forward looking statements

Information set forth in this communication contains forward-looking statements, which involve a number of risks and uncertainties. Such forward-looking statements include, but are not limited to, statements about the anticipated benefits of Evotec's products, the anticipated timing and results of Evotec's clinical and preclinical programs, and other statements that are not historical facts. Evotec cautions readers that any forward-looking information is not a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking information as a result of risks and uncertainties relating to: the need to adapt to significant technological change; use and protection of intellectual property; as well as other economic, business and/or competitive factors; and the effect of exchange rate fluctuations on international operations.

The risks included above are not exhaustive. Evotec expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in the parties' expectations or any change in events, conditions or circumstances on which any such statement is based.

Additional Information

Renovis filed a Current Report on Form 8-K with the Securities and Exchange Commission on September 24, 2007, that includes as an exhibit the Agreement and Plan of Merger between Evotec and Renovis. Evotec intends to file a Registration Statement on Form F-4 with the Securities and Exchange Comm
'/>"/>

SOURCE Evotec AG
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Autopsy reports could be valuable and informative
2. China reports declining number of SARS Cases
3. Russia Reports First SARS Case
4. Research reports that c-section deliveries are rising
5. Jharkhand reports 13,000 Malaria cases
6. Uganda Reports Failure To Contain Sleeping Sickness
7. WHO reports 36 million deaths world wide due to chronic diseases
8. Reports of Hantavirus infection in India raise concerns
9. Controversy Surrounding The HIV Positive Reports Of One-Year Girl In Kerala
10. China Reports Yet Another Bird Flu Case
11. China reports seventh bird flu victim
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2008)...p://www.aronowitzmd.com [Los Angeles cosmetic sur...e in plastic surgery procedures for post bariatric...be necessary for these patients, health and wellne...pecialty of procedures for after weight loss. , ...ust 29, 2008 -- Bariatric surgery improves the hea...
(Date:8/28/2008)...onventional therapy, study found , , THU...a treadmill improves brain function and fitness fo...gh the usual rehabilitation program, a new study f...s have," said study researcher Dr. Andreas Luft, a...tation at the University of Zurich in Switzerland....
(Date:8/28/2008)...l efforts of the Maryland Medicaid contract, HARR...onal medical,management firm, appointed Lenaye Law...r. Dr. Lawyer will oversee all clinical aspects of...nt Valley, Maryland Harrisburg,office., "Dr. Lawy...land," said,Alice Stollenwerk Petrulis, MD, FACP, ...
(Date:8/28/2008)... physical, especially for the impaired, study says...-- A new study says that 13 percent of American se...use. , The University of Chicago researchers s... being taken advantage of financially (3.5 percent... found that seniors with physical impairments were...
Breaking Medicine News(10 mins):Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 2Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 3Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 4Health News:Treadmill Workouts Help Stroke Survivors 2Health News:Lenaye Lawyer, MD, FACOG, Named KePRO Medical Director 2Health News:13% of Seniors Report Being Mistreated 2
...sandro Remo Zanetti and his colleagues from Instit...ination with Hepatitis B produces the required con... of the patients for long periods//. The researche...inst Hepatitis B vaccination are present in the bl...
... infections are a major cause for hospitalization ...ection are risks for subsequent amputation. Ischem...betes combine to produce tissue necrosis and ulcer...lly polymicrobial in nature. Early recognition of ...
...morphins are highly powerful a tool for pain manag...rived from the opium poppy. It has previously been...erns// of side effects by virtue of their hard-wir...ceptors. Such receptors, known as u-opioids, appea...
... study conducted on factors that predispose to dri...’s tendency to do things like lie, steal or skip s...at a very early age of 12, 13 or 14//. The study ...the issue and is a contradiction to the existing a...
Other Medicine News:Health News:Booster dose not required for Hepatitis B Vaccination 2Health News:The Polymicrobial Nature Of Diabetic Foot Infections 2Health News:Ambiguous Efficacy Of Opioid Drugs In Chronic Inflammatory Joint Pain Relief 2
(Date:8/27/2008)...ght in Parts of Bucks, Delaware, Montgomery,Phila...swire-USNewswire/ -- After encouraging,results fol...epartment of,Environmental Protection will continu...gainst the mosquito-borne West Nile virus., Targe... 8 p.m. and,midnight in portions of Bucks, Delawar...
(Date:8/27/2008)...CADE, melphalan and prednisone arm demonstrated a,...cent complete response -, CAMBRIDGE, Mass., Aug. ... Company today announced the publication of result...A(1) trial in this week,s edition of the,New Engla...ficant survival,benefit and a 30 percent complete ...
(Date:8/27/2008)...st 27 /-, - Oralair(R) Gra...harmacodynamic Study Conducted in an Allergen Chal...ghly positive results of a new study,conducted in ...n Oralair(R) Grasses included 86 adult patients ex...atment durations: 1 week, 1 month,2 and 4 months ...
(Date:8/27/2008)...a, from BLISS-52 trial, expected by mid-2009 - - ... by fall 2009 -, ROCKVILLE, Md., Aug. 27 /PRNewsw...daq: HGSI ) today announced it has completed enro...of two pivotal Phase 3,randomized clinical trials ...tive systemic lupus erythematosus (SLE). Belimumab...
Breaking Medicine Technology:DEP to Complete Aerial Mosquito Treatments to Stem West Nile Virus in Southeastern Counties 2DEP to Complete Aerial Mosquito Treatments to Stem West Nile Virus in Southeastern Counties 3New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 2New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 3New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 4New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 5New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 6Stallergenes: New Study VO 56 Highly Positive Results Conducted in an Allergen Challenge Chamber 2Stallergenes: New Study VO 56 Highly Positive Results Conducted in an Allergen Challenge Chamber 3Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 2Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 3Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 4Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 5Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 6Three Astex Drug Candidates to be Presented at the 2007 American Society of Hematology Annual Meeting 1994 1Three Astex Drug Candidates to be Presented at the 2007 American Society of Hematology Annual Meeting 1994 2Three Astex Drug Candidates to be Presented at the 2007 American Society of Hematology Annual Meeting 1994 3Smokers Cost Medicaid System Nearly 2410 Billion 7170 1Smokers Cost Medicaid System Nearly 2410 Billion 7170 2Smokers Cost Medicaid System Nearly 2410 Billion 7170 3Sigma Aldrich Achieves Double Accreditation as a Certified Reference Material Producer Following ISO IEC 17025 and ISO Guide 34 1992 1Sigma Aldrich Achieves Double Accreditation as a Certified Reference Material Producer Following ISO IEC 17025 and ISO Guide 34 1992 2Meniscal damage and the development of persistent knee pain 7168 1Meniscal damage and the development of persistent knee pain 7168 2Meniscal damage and the development of persistent knee pain 7168 3
...ults Indicate Bioequivalent Pharmacokinetics With ...X-514, SAN DIEGO, April 25, 2007 /PRNewswire-First...rmaceutical research and,development company focus...es for the treatment of cancer and infectious dise...nical pharmacokinetic,testing of ANX-514 (docetaxe...
...SEL, Switzerland, April 25, 2007 - Basilea Pharmac...udy results showing that,patients with severe chro... alitretinoin. In two previous randomized clinical... treating severe,chronic hand eczema in patients r...l demonstrated that patients responsive to initial...
Other Medicine Technology:ADVENTRX Announces Positive Data From Preclinical Pharmacokinetic,Testing of ANX-514 (Docetaxel Emulsion) 2ADVENTRX Announces Positive Data From Preclinical Pharmacokinetic,Testing of ANX-514 (Docetaxel Emulsion) 3ADVENTRX Announces Positive Data From Preclinical Pharmacokinetic,Testing of ANX-514 (Docetaxel Emulsion) 4ADVENTRX Announces Positive Data From Preclinical Pharmacokinetic,Testing of ANX-514 (Docetaxel Emulsion) 5Basilea Reports Positive Re-treatment Results from a Second Phase,III Trial of Alitretinoin for Patients with Severe Chronic Hand,Eczema 2Basilea Reports Positive Re-treatment Results from a Second Phase,III Trial of Alitretinoin for Patients with Severe Chronic Hand,Eczema 3Basilea Reports Positive Re-treatment Results from a Second Phase,III Trial of Alitretinoin for Patients with Severe Chronic Hand,Eczema 4Basilea Reports Positive Re-treatment Results from a Second Phase,III Trial of Alitretinoin for Patients with Severe Chronic Hand,Eczema 5
Flexible vinyl with a rigid bite block. Guedel-style with three internal channels. Individually packaged, 48 per case. Latex Free.
Includes one of each size airway. Plastic. Color coded for size. Single use. Non-Sterile.
Our soft guedel airway is clear and has a color coded bite block. Airway has a smooth finish and is Latex Free. Recommended for single use. Non-Sterile.
Rsch color coded Guedel airways offer our best value on oropharyngeal airways. They uniquely combine color coding for size and flexible material without a premium price. Color coded airways are latex
Medicine Products: